

<b>Patient Information:</b>
Name: _____
DOB: _____

**Pediatric COVID-19 Monoclonal Antibody Referral Form**

*This form must be completed by the referring provider and will be uploaded as a PDF to the patient's chart in EPIC via Media Manager function Complete the required fields (annotated by \*) and submit this referral form along with the order form (page 2) via fax to: 859-218-7670*

**Indication\*:** patient must meet both of the below criteria in addition to others listed below

This patient is:

- 12 years of age or older
- At least 40 kg (documented weight: \_\_\_\_\_ kg (date obtained: \_\_\_\_\_ (MM/DD/YYYY))

**Treatment** (if selected, complete the below fields)

1.  Mild to moderate COVID-19 infection with **positive** results of direct SARS-CoV-2 viral testing (PCR or antigen):
  - Date of SARS-CoV-2 Test: \_\_\_\_\_ (MM/DD/YYYY)
  - Date of Symptom Onset: \_\_\_\_\_ (MM/DD/YYYY)

**AND**

2.  At least **two** of the following symptoms: *select all that apply*
  - Fever
  - Cough
  - Sore Throat
  - Malaise
  - Headache
  - Myalgias
  - Gastrointestinal Symptoms
  - Shortness of Breath
  - Other: \_\_\_\_\_

**Post-Exposure Prophylaxis** (if selected, complete the below fields)

1.  Not fully vaccinated **OR**
  - Not expected to mount an adequate immune response to complete SARS-CoV-2 vaccination

**AND**

2.  Have been exposed to an individual infected with SARS CoV-2 consistent with close contact criteria per [CDC](#) **OR**
  - Who are at high risk of exposure to an individual infected with SARS-CoV-2 because of an occurrence of SARS-CoV-2 infection in other individuals in the same institutional setting

**Select the Patient's High Risk Criteria\*** outlined in the EUA include the following:

- Obesity or being overweight (BMI  $\geq$  85% for their age and gender on [CDC growth charts](#))
- Chronic kidney disease
- Diabetes
- Immunosuppressive disease or immunosuppressive treatment
- Cardiovascular disease (including congenital heart disease)
- Sickle cell disease
- Pregnant
- Chronic lung disease (moderate to severe asthma, interstitial lung disease, cystic fibrosis and pulmonary hypertension)
- Neurodevelopmental disorders or other conditions that confer medical complexity (i.e., cerebral palsy, genetic/metabolic syndromes, severe congenital anomalies)
- Medical-related technological dependent (i.e., tracheostomy, gastrostomy, positive pressure ventilation not related to COVID-19)
- Other medical conditions/factors associated with increased risk for progression to severe COVID, per [CDC website](#)  
If other, please specify: \_\_\_\_\_

**I have provided the patient's legal guardian with a copy of the Fact Sheet for Parents and Caregivers** ([English](#); [Spanish](#))\*

**Legal Attestation\*:**

\_\_\_\_\_ (Last Name, First Name) is a \_\_\_\_\_ (age) year old \_\_\_\_\_ (gender) under my care for COVID-19. I have assessed my patient as eligible to receive casirivimab and imdevimab under the FDA Emergency Use Authorization (EUA). I have reviewed the mandatory requirements for drug use within the Fact Sheet for Health Care Providers and obtained approval for use according to institutional policy. I have provided information consistent with the Fact Sheet for Patients and Parents/Caregivers EUA of casirivimab and imdevimab and given the patient/legal representative a copy. The patient/legal representative was informed of the potential risks and benefits of casirivimab and imdevimab, alternatives to casirivimab and imdevimab, and that casirivimab and imdevimab is an unapproved drug that is authorized for use under EUA. The patient or patient's legal representative has expressly agreed to this treatment.

_____ Signature, Referring Provider	_____ Date (MM/DD/YYYY)	_____ Contact Information
--	----------------------------	------------------------------

**Pediatric COVID-19 Monoclonal Antibody Order Form**

Complete the required fields (annotated by \*) and submit this order form along with the referral form (page 1) via fax to: **859-218-7670**

**Patient Name\*:** \_\_\_\_\_ **Date of Birth\*:** \_\_\_\_\_

**Legal Guardian Name\*:** \_\_\_\_\_ **Phone Number\*:** \_\_\_\_\_

**Allergies\*:** \_\_\_\_\_

No Known Drug Allergies

**Indication\*:**

- Treatment
- Post-Exposure Prophylaxis

**Casirivimab/Imdevimab Order:**

Intravenous Administration

casirivimab 600 mg, imdevimab 600 mg in sodium chloride 0.9% 100 mL IV piggyback administered over 30 minutes

*If intravenous access cannot be obtained the subcutaneous order will be activated for use as selected below*

Subcutaneous Administration

casirivimab 300 mg (2.5 mL) subcutaneous every 5 minutes for 2 doses as needed for intravenous access difficulty

**AND**

imdevimab 300 mg (2.5 mL) subcutaneous every 5 minutes for 2 doses as needed for intravenous access difficulty

**Additional Drug Therapy Orders:**

- lidocaine (Anecream) 1 application topically as needed for line insertion **OR**
- lidocaine (Anecream) 4 applications topically as needed for subcutaneous injections

**Nursing Orders:**

- Insert peripheral IV
- Clinically monitor patient during administration and observe patient for at least 1 hour after administration is complete; monitor vital signs at baseline, at end of the administration and 1 hour after administration is completed

**Hypersensitivity Orders:**

- Hypersensitivity Management per University of Kentucky HealthCare Protocol
- hydrocortisone \_\_\_\_ \*mg (2 mg/kg (max: 100 mg)) intravenous **or** prednisolone \_\_\_\_ \*mg (2 mg/kg (max: 60 mg)) oral as needed for Grade 2, 3 or 4 infusion reactions
- diphenhydramine \_\_\_\_ \*mg (1 mg/kg (max: 50 mg)) intravenous/oral as needed for Grade 2, 3 or 4 infusion reactions
- famotidine 20 mg (0.5 mg/kg (max: 20 mg)) intravenous/oral as needed for Grade 2, 3 or 4 infusion reactions
- albuterol 108 (90 base) mcg/act inhaler 4 puffs as needed for Grade 3 or 4 infusion reactions
- epinephrine 0.3 mg intramuscular as needed for Grade 4 infusion reactions

\_\_\_\_\_  
Signature, Referring Provider

\_\_\_\_\_  
Date (MM/DD/YYYY)

\_\_\_\_\_  
Telephone Number

\_\_\_\_\_  
Printed Name, Referring Provider

\_\_\_\_\_  
Credentials

\_\_\_\_\_  
License Number/DEA Number

\_\_\_\_\_  
Address

\_\_\_\_\_  
City

\_\_\_\_\_  
State

\_\_\_\_\_  
Zip Code

## Pediatric COVID-19 Monoclonal Antibody Outpatient Therapy Workflow for Outside Referrals

*Patients, regardless of where they test positive, may have the therapy ordered after they speak with their provider, assuming they qualify. The product is currently provided at no cost from the manufacturer, so the only charge is for the chair time in the infusion suite*

Emergency use of casirivimab/imdevimab has been [authorized](#) by the Food and Drug Administration (FDA). As casirivimab/imdevimab is not FDA approved for this defined patient population, the following fact sheet containing drug information should be carefully reviewed when considering use: [Casirivimab/Imdevimab EUA - Fact Sheet for Healthcare Providers](#)

### Dosing:

- For Post-Exposure Prophylaxis AND Treatment: 600 mg of casirivimab AND 600 mg of imdevimab
  - The preferred route of administration will be intravenously [if peripheral intravenous access cannot be obtained, subcutaneous administration will be used]
  - Clinically monitor patients during treatment administration (regardless of route) and for at least **1 hour** after dosing is complete

### Screening and Selection of Appropriate Candidates:

**It is important to note that COVID-19 does not affect all population groups equally.**

- The risk of severe COVID-19 increases as the number of underlying medical conditions increases in an individual.
- Long-standing systemic health and social inequities have put various groups of people at increased risk of getting sick and dying from COVID-19, including many **racial and ethnic minority groups and people with disabilities**

### Inclusion Criteria:

- Pediatric patients 12 to < 18 years of age **AND** weighing at least 40 kg meeting high risk criteria (below) for developing a severe COVID-19 infection and are currently outpatient and **not** hospitalized for COVID-19 (as listed per exclusion criteria below)

Treatment	Post-Exposure Prophylaxis
Mild-to-moderate COVID-19 infection with positive results of direct SARS-CoV-2 viral testing (PCR or antigen) with the following: <ul style="list-style-type: none"> <li>• Symptomatic (at least 2 of the following: fever, cough, sore throat, malaise, headache, myalgias, gastrointestinal symptoms, shortness of breath)</li> <li>• Within 10 days of symptom onset</li> </ul>	Not fully vaccinated OR who are not expected to mount an adequate immune response to complete SARS-CoV-2 vaccination <b>AND</b> <ul style="list-style-type: none"> <li>• Have been exposed to an individual infected with SARS-CoV-2 consistent with close contact criteria per <a href="#">CDC</a> <b>or</b></li> <li>• Who are at high risk of exposure to an individual infected with SARS-CoV-2 because of an occurrence of SARS-CoV-2 infection in other individuals in the same institutional setting</li> </ul>

**High risk criteria** outlined in the EUA include the following:

- |   |   |
|---|---|
| <ul style="list-style-type: none"> <li>• Obesity or being overweight (BMI <math>\geq</math> 85% for their age and gender on <a href="#">CDC growth charts</a>)</li> <li>• Chronic kidney disease</li> <li>• Diabetes</li> <li>• Immunosuppressive disease or immunosuppressive treatment</li> <li>• Cardiovascular disease (including congenital heart disease)</li> <li>• Sickle cell disease</li> <li>• Pregnant</li> </ul> | <ul style="list-style-type: none"> <li>• Chronic lung disease (moderate to severe asthma, interstitial lung disease, cystic fibrosis and pulmonary hypertension)</li> <li>• Neurodevelopmental disorders or other conditions that confer medical complexity (i.e., cerebral palsy, genetic/metabolic syndromes, severe congenital anomalies)</li> <li>• Medical-related technological dependent (i.e., tracheostomy, gastrostomy, positive pressure ventilation not related to COVID-19)</li> <li>• Other medical conditions/factors associated with increased risk for progression to severe COVID, per <a href="#">CDC website</a></li> </ul> |
|---|---|

### Exclusion Criteria:

- Hospitalization due to COVID-19
- Requiring oxygen therapy due to COVID-19, including those patients on chronic oxygen therapy who require an increase in baseline oxygen flow rate due to COVID-19
- Hypersensitivity to product or ingredients
- Co-morbidity requiring surgery within 7 days or considered life threatening within 29 days

**Casirivimab/Imdevimab Infusion Referral Process:** *Patients will be scheduled as referrals are received, with priority given to patients receiving casirivimab/imdevimab for the mild-to-moderate symptomatic COVID-19 infection treatment indication*

**Process**

**Responsible Party**

Patient is deemed candidate for casirivimab/imdevimab as treatment or post-exposure prophylaxis upon review of patient specific criteria outlined above per the EUA

Referring Provider



Legal Guardian is informed of alternatives to receiving casirivimab/imdevimab and that casirivimab/imdevimab is an unapproved drug authorized for use under FDA EUA. Legal Guardian is counseled and provided with Fact Sheet for Parents and Caregivers ([English](#); [Spanish](#))

Referring Provider



Complete and sign the casirivimab/imdevimab EUA criteria referral **and** order forms and submit to 859-218-7670.  
[Tip Sheet Found on Website]

Referring Provider



Upon receipt of referral and order forms, scheduling staff will register the patient in to EPIC. The scheduler will call patient/legal guardian and schedule infusion appointment at next available infusion date and time. During this call, the scheduler will provide guidance to the patient/legal guardian on parking, registration, and arrival.

Designated Scheduler



Scheduler will be upload the completed referral and order forms to the patient's medical record through EPIC "Media Manager".

Designated Scheduler



Within 48 to 72 hours of casirivimab/imdevimab infusion, the patient must have a documented telehealth visit in order to evaluate clinical status and ensure no disease progression or escalation of care is warranted.

Referring Provider



Within 7 to 10 days of casirivimab/imdevimab infusion, the referring provider or designee (i.e., RN) completes a telephone call with patient or caregiver to evaluate clinical status and ensure no disease progression or escalation of care is warranted.

Referring Provider or Designee  
(i.e., Nurse)



Report all medication errors and adverse events occurring during casirivimab/imdevimab use and consider potentially attributable to casirivimab/imdevimab within 7 calendar days from onset of event:

Any Patient Care Provider  
(i.e., Referring Provider,  
Pharmacist, Nurse, etc.)

- [UKHC SI Report](#) (reported through this system only if reaction occurs at UKHC)
- FDA MedWatch: [www.fda.gov/medwatch/report.htm](http://www.fda.gov/medwatch/report.htm)
  - [Follow all instructions for reporting within the EUA Prescribing Information Listed in the Health Care Provider Fact Sheet](#)

## COMPLETING THE REQUIRED PEDIATRIC COVID-19 MONOCLONAL ANTIBODY REFERRAL FORM

**Step 1:** Complete the Patient Specific Information



**Patient Information:**

Name:

DOB:

### Pediatric COVID-19 Monoclonal Antibody Referral Form

*This form must be completed by the referring provider and will be uploaded as a PDF to the patient's chart in EPIC via Media Manager function Complete the required fields (annotated by \*) and submit this referral form along with the order form (page 2) via fax to: 859-218-7670*

**Step 2:** Review patient specific information to confirm that patient meets the Emergency Use Authorization (EUA) criteria as outlined in the *Interim Guidance for the Outpatient Management of SARS-CoV-2 (COVID-19) with Monoclonal Antibody Therapy in Pediatric Patients*

- Step 2a:** Indicate that the patient is 12 years of age or older **AND** weights at least 40 kg (list the patient's weight and date in which that weight was obtained)

These boxes can be selected within the PDF or simply annotate with a check mark (v) or X

**Indication:** *patient must meet both of the below criteria in addition to others listed below*  
This patient is:

- 12 years of age or older **AND**
- At least 40 kg (documented weight:  kg (date obtained:  (MM/DD/YYYY))

- Step 2b:** Indicate the specific indication for use: **treatment** or **post-exposure prophylaxis**. Based on the indication selected, complete the required fields

Treatment

OR

Post-Exposure Prophylaxis

- Treatment** (if selected, complete the below fields)
- Mild to moderate COVID-19 infection with **positive** results of direct SARS-CoV-2 viral testing (PCR or antigen):
    - Date of SARS-CoV-2 Test:  (MM/DD/YYYY)
    - Date of Symptom Onset:  (MM/DD/YYYY)

**AND**
  - At least **two** of the following symptoms: *select all that apply*

<input type="checkbox"/> Fever	<input type="checkbox"/> Cough	<input type="checkbox"/> Sore Throat
<input type="checkbox"/> Malaise	<input type="checkbox"/> Headache	<input type="checkbox"/> Myalgias
<input type="checkbox"/> Gastrointestinal Symptoms	<input style="width: 100px;" type="text"/>	
<input type="checkbox"/> Shortness of Breath	<input type="checkbox"/> Other: <input style="width: 100px;" type="text"/>	

- Post-Exposure Prophylaxis** (if selected, complete the below fields)
- Not fully vaccinated **OR**
    - Not expected to mount an adequate immune response to complete SARS-CoV-2 vaccination

**AND**
  - Have been exposed to an individual infected with SARS CoV-2 consistent with close contact criteria per [CDC](#) **OR**
    - Who are at high risk of exposure to an individual infected with SARS-CoV-2 because of an occurrence of SARS-CoV-2 infection in other individuals in the same institutional setting

Complete Item 1 and 2

Select an Item in 1 and 2

# Tip Sheet

- **Step 2c:** Select the high risk criteria that align with the being referred for monoclonal antibody administration

Select the Patient's High Risk Criteria outlined in the EUA include the following:

<input type="checkbox"/> Obesity or being overweight (BMI $\geq$ 85% for their age and gender on <a href="#">CDC growth charts</a> )	<div style="border: 2px solid red; padding: 5px; text-align: center;">REMINDER: These boxes can be selected within the PDF or simply annotate with a check mark (✓) or X</div>
<input type="checkbox"/> Chronic kidney disease	
<input type="checkbox"/> Diabetes	
<input type="checkbox"/> Immunosuppressive disease or immunosuppressive treatment	
<input type="checkbox"/> Cardiovascular disease (including congenital heart disease)	
<input type="checkbox"/> Sickle cell disease	
<input type="checkbox"/> Pregnant	
<input type="checkbox"/> Chronic lung disease (moderate to severe asthma, interstitial lung disease, cystic fibrosis and pulmonary hypertension)	
<input type="checkbox"/> Genetic/metabolic	
<input type="checkbox"/> Neurodevelopmental disorders or other conditions that confer medical complexity (i.e., cerebral palsy, syndromes, severe congenital anomalies)	
<input type="checkbox"/> Not related to	<input type="checkbox"/> Medical-related technological dependent (i.e., tracheostomy, gastrostomy, positive pressure ventilator)
<input type="checkbox"/> COVID-19	<input type="checkbox"/> Other medical conditions/factors associated with increased risk for progression to severe COVID, per <a href="#">CDC website</a>
	If other, please specify: _____

- **Step 2d:** Attest that you have provided the patient's legal guardian with the Fact Sheet. This is a requirement per EUA criteria!

<input type="checkbox"/> I have provided the patient's legal guardian with a copy of the Fact Sheet for Parents and Caregivers ( <a href="#">English</a> ; <a href="#">Spanish</a> )	<div style="border: 2px solid red; padding: 5px; text-align: center;">To attest, simply annotate this box within the PDF formatting or annotate with a check mark (✓) or X</div>	<div style="border: 2px solid red; padding: 5px; text-align: center;">Links are available to the fact sheet here!</div>

**Step 3:** Complete the legal attestation that has been previously reviewed and approved for EUA therapies offered at UK HealthCare – this includes COVID-19 monoclonal antibody therapy!

**Legal Attestation:**

\_\_\_\_\_(Last Name, First Name) is a \_\_\_\_\_ (age) year old \_\_\_\_\_ (gender) under my care for COVID-19. I have assessed my patient as eligible to receive casirivimab and imdevimab under the FDA Emergency Use Authorization (EUA). I have reviewed the mandatory requirements for drug use within the Fact Sheet for Health Care Providers and obtained approval for use according to institutional policy. I have provided information consistent with the Fact Sheet for Patients and Parents/Caregivers EUA of casirivimab and imdevimab and given the patient/legal representative a copy. The patient/legal representative was informed of the potential risks and benefits of casirivimab and imdevimab, alternatives to casirivimab and imdevimab, and that casirivimab and imdevimab is an unapproved drug that is authorized for use under EUA. The patient or patient's legal representative has expressly agreed to this treatment.

**Step 4:** Sign, date, and list contact information as the referring provider. This signature can be completed through a digital signature **OR** alternative means of legal signature (i.e., ink or stamp)

<input type="text"/>	<input type="text"/>	<input type="text"/>
Signature, Referring Provider	Date (MM/DD/YYYY)	Contact Information

## COMPLETING THE REQUIRED PEDIATRIC COVID-19 MONOCLONAL ANTIBODY ORDER FORM

**Step 1:** Complete the Patient Specific Information, including the name and contact information of the patient's legal guardian [this information will be needed for scheduling purposes!]



### Pediatric COVID-19 Monoclonal Antibody Order Form

Complete the required fields (annotated by \*) and submit this order form along with the referral form (page 1) via fax to: **859-218-7670**

Patient Name\*:  Date of Birth\*:   
Legal Guardian Name\*:  Phone Number\*:   
Allergies\*:   
 No Known Drug Allergies

**Step 2:** Select the appropriate indication (this should be the same indication as page 1)

**Indication\*:**

- Treatment
- Post-Exposure Prophylaxis

To attest, simply annotate this box within the PDF formatting or annotate with a check mark (✓) or X

**Step 3:** Review the selected orders for casirivimab/imdevimab – these have already been selected for you based on current workflow at UK HealthCare.

**Casirivimab/Imdevimab Order:**

Intravenous Administration

- casirivimab 600 mg, imdevimab 600 mg in sodium chloride 0.9% 100 mL IV piggyback administered over 30 minutes

*If intravenous access cannot be obtained the subcutaneous order will be activated for use as selected below*

Subcutaneous Administration

- casirivimab 300 mg (2.5 mL) subcutaneous every 5 minutes for 2 doses as needed for intravenous access difficulty
- AND**
- imdevimab 300 mg (2.5 mL) subcutaneous every 5 minutes for 2 doses as needed for intravenous access difficulty

**Additional Drug Therapy Orders:**

- lidocaine (Anecream) 1 application topically as needed for line insertion **OR**
- lidocaine (Anecream) 4 applications topically as needed for subcutaneous injections

**Nursing Orders:**

- Insert peripheral IV
- Clinically monitor patient during administration and observe patient for at least 1 hour after administration is complete; monitor vital signs at baseline, at end of the administration and 1 hour after administration is completed

- **Step 3a:** Be sure to complete the patient specific dosing for the hypersensitivity kit medications – **hydrocortisone, prednisolone and diphenhydramine**

**Hypersensitivity Orders:**

- Hypersensitivity Management per University of Kentucky HealthCare Protocol
- hydrocortisone \_\_\_\_ \*mg (2 mg/kg (max: 100 mg)) intravenous **or** prednisolone \_\_\_\_ \*mg (2 mg/kg (max: 60 mg)) oral as needed for Grade 2, 3 or 4 infusion reactions
- diphenhydramine \_\_\_\_ \*mg (1 mg/kg (max: 50 mg)) intravenous/oral as needed for Grade 2, 3 or 4 infusion reactions
- famotidine 20 mg (0.5 mg/kg (max: 20 mg)) intravenous/oral as needed for Grade 2, 3 or 4 infusion reactions
- albuterol 108 (90 base) mcg/act inhaler 4 puffs as needed for Grade 3 or 4 infusion reactions
- epinephrine 0.3 mg intramuscular as needed for Grade 4 infusion reactions

**Step 4:** Sign, date, and list contact information (including address) along with credentials, license number and DEA number as the referring provider. This signature can be completed through a digital signature **OR** alternative means of legal signature (i.e., ink or stamp)

Signature, Referring Provider	Date (MM/DD/YYYY)	Telephone Number	
Printed Name, Referring Provider	Credentials	License Number/DEA Number	
Address	City	State	Zip Code

**Once Page 1 (Referral Form) and Page 2 (Order Form) are completed, fax to 859-218-7670. A team member will contact your patient (or patient’s legal guardian) to schedule their infusion.**

These forms can be printed and the information completed by hand or the referral and order form can be digitally completed and signed.



<b>Patient Information:</b>
Name: _____
DOB: _____

**Pediatric COVID-19 Monoclonal Antibody Referral Form**

*This form must be completed by the referring provider and will be uploaded as a PDF to the patient's chart in EPIC via Media Manager function Complete the required fields (annotated by \*) and submit this referral form along with the order form (page 2) via fax to: 859-218-7670*

**Indication\*:** patient must meet both of the below criteria in addition to others listed below

This patient is:

- 12 years of age or older
- At least 40 kg (documented weight: \_\_\_\_\_ kg (date obtained: \_\_\_\_\_ (MM/DD/YYYY))

**Treatment** (if selected, complete the below fields)

1.  Mild to moderate COVID-19 infection with **positive** results of direct SARS-CoV-2 viral testing (PCR or antigen):
  - Date of SARS-CoV-2 Test: \_\_\_\_\_ (MM/DD/YYYY)
  - Date of Symptom Onset: \_\_\_\_\_ (MM/DD/YYYY)

**AND**

2.  At least **two** of the following symptoms: *select all that apply*
  - Fever
  - Cough
  - Sore Throat
  - Malaise
  - Headache
  - Myalgias
  - Gastrointestinal Symptoms
  - Shortness of Breath
  - Other: \_\_\_\_\_

**Post-Exposure Prophylaxis** (if selected, complete the below fields)

1.  Not fully vaccinated **OR**
  - Not expected to mount an adequate immune response to complete SARS-CoV-2 vaccination

**AND**

2.  Have been exposed to an individual infected with SARS CoV-2 consistent with close contact criteria per [CDC](#) **OR**
  - Who are at high risk of exposure to an individual infected with SARS-CoV-2 because of an occurrence of SARS-CoV-2 infection in other individuals in the same institutional setting

859-218-7670

**Select the Patient's High Risk Criteria\*** outlined in the EUA include the following:

- Obesity or being overweight (BMI  $\geq$  85% for their age and gender on [CDC growth charts](#))
- Chronic kidney disease
- Diabetes
- Immunosuppressive disease or immunosuppressive treatment
- Cardiovascular disease (including congenital heart disease)
- Sickle cell disease
- Pregnant
- Chronic lung disease (moderate to severe asthma, interstitial lung disease, cystic fibrosis and pulmonary hypertension)
- Neurodevelopmental disorders or other conditions that confer medical complexity (i.e., cerebral palsy, genetic/metabolic syndromes, severe congenital anomalies)
- Medical-related technological dependent (i.e., tracheostomy, gastrostomy, positive pressure ventilation not related to COVID-19)
- Other medical conditions/factors associated with increased risk for progression to severe COVID, per [CDC website](#)  
If other, please specify: \_\_\_\_\_

I have provided the patient's legal guardian with a copy of the Fact Sheet for Parents and Caregivers ([English](#); [Spanish](#))\*

**Legal Attestation\*:**

\_\_\_\_\_ (Last Name, First Name) is a \_\_\_\_\_ (age) year old \_\_\_\_\_ (gender) under my care for COVID-19. I have assessed my patient as eligible to receive casirivimab and imdevimab under the FDA Emergency Use Authorization (EUA). I have reviewed the mandatory requirements for drug use within the Fact Sheet for Health Care Providers and obtained approval for use according to institutional policy. I have provided information consistent with the Fact Sheet for Patients and Parents/Caregivers EUA of casirivimab and imdevimab and given the patient/legal representative a copy. The patient/legal representative was informed of the potential risks and benefits of casirivimab and imdevimab, alternatives to casirivimab and imdevimab, and that casirivimab and imdevimab is an unapproved drug that is authorized for use under EUA. The patient or patient's legal representative has expressly agreed to this treatment.

_____ Signature, Referring Provider	_____ Date (MM/DD/YYYY)	_____ Contact Information
--	----------------------------	------------------------------

**Pediatric COVID-19 Monoclonal Antibody Order Form**

Complete the required fields (annotated by \*) and submit this order form along with the referral form (page 1) via fax to: **859-218-7670**

**Patient Name\*:** \_\_\_\_\_ **Date of Birth\*:** \_\_\_\_\_

**Legal Guardian Name\*:** \_\_\_\_\_ **Phone Number\*:** \_\_\_\_\_

**Allergies\*:** \_\_\_\_\_

No Known Drug Allergies

**Indication\*:**

- Treatment
- Post-Exposure Prophylaxis

**Casirivimab/Imdevimab Order:**

Intravenous Administration

casirivimab 600 mg, imdevimab 600 mg in sodium chloride 0.9% 100 mL IV piggyback administered over 30 minutes

*If intravenous access cannot be obtained the subcutaneous order will be activated for use as selected below*

Subcutaneous Administration

casirivimab 300 mg (2.5 mL) subcutaneous every 5 minutes for 2 doses as needed for intravenous access difficulty

**AND**

imdevimab 300 mg (2.5 mL) subcutaneous every 5 minutes for 2 doses as needed for intravenous access difficulty

**Additional Drug Therapy Orders:**

- lidocaine (Anecream) 1 application topically as needed for line insertion **OR**
- lidocaine (Anecream) 4 applications topically as needed for subcutaneous injections

**Nursing Orders:**

- Insert peripheral IV
- Clinically monitor patient during administration and observe patient for at least 1 hour after administration is complete; monitor vital signs at baseline, at end of the administration and 1 hour after administration is completed

**Hypersensitivity Orders:**

- Hypersensitivity Management per University of Kentucky HealthCare Protocol
- hydrocortisone \_\_\_\_ \*mg (2 mg/kg (max: 100 mg)) intravenous **or** prednisolone \_\_\_\_ \*mg (2 mg/kg (max: 60 mg)) oral as needed for Grade 2, 3 or 4 infusion reactions
- diphenhydramine \_\_\_\_ \*mg (1 mg/kg (max: 50 mg)) intravenous/oral as needed for Grade 2, 3 or 4 infusion reactions
- famotidine 20 mg (0.5 mg/kg (max: 20 mg)) intravenous/oral as needed for Grade 2, 3 or 4 infusion reactions
- albuterol 108 (90 base) mcg/act inhaler 4 puffs as needed for Grade 3 or 4 infusion reactions
- epinephrine 0.3 mg intramuscular as needed for Grade 4 infusion reactions

\_\_\_\_\_  
Signature, Referring Provider

\_\_\_\_\_  
Date (MM/DD/YYYY)

\_\_\_\_\_  
Telephone Number

\_\_\_\_\_  
Printed Name, Referring Provider

\_\_\_\_\_  
Credentials

\_\_\_\_\_  
License Number/DEA Number

\_\_\_\_\_  
Address

\_\_\_\_\_  
City

\_\_\_\_\_  
State

\_\_\_\_\_  
Zip Code